Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics' stock price has experienced significant declines over the past six months and year. The stock was down 66.56% between March 24, 2025, and March 20, 2026. Over the last six months, the stock has declined by 58.1% and by 70.03%. The stock price as of March 20, 2026, was $6.52 per share. Recent events impacting the stock include the Q4 2025 earnings report, which showed a net loss of $3.0 million. Cadrenal Therapeutics completed an End-of-Phase 2 meeting with the FDA on March 26, 2026, to discuss its planned Phase 3 trial of CAD-1005 for heparin-induced thrombocytopenia. The company reported Phase 2 study results showing a greater than 25% absolute reduction in thrombotic events in patients treated with CAD-1005 compared to placebo. Seven months prior to March 2026, Cadrenal Therapeutics expanded its pipeline with a portfolio acquisition worth up to $15 million. As of December 31, 2025, Cadrenal had cash and cash equivalents of $4.0 million.

As a clinical-stage biopharmaceutical company, Cadrenal Therapeutics' revenue generation primarily stems from the potential sale of proprietary therapies, licensing agreements, and strategic partnerships. Therefore, the concept of demand seasonality is not directly applicable to Cadrenal Therapeutics' products and services at this stage of its development. The demand for its therapies, once approved, would be driven by medical need and adoption within the healthcare system, rather than seasonal fluctuations.

Cadrenal Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions, particularly in cardiovascular and renal diseases. The company's core business revolves around the development and commercialization of proprietary therapies, including Tecarfarin, CAD-1005, and Frunexian. Tecarfarin is a late-stage, reversible oral vitamin K antagonist designed to prevent blood clots in patients with rare cardiovascular conditions. CAD-1005 is a phase 3-ready 12-LOX inhibitor being evaluated for the treatment of suspected heparin-induced thrombocytopenia. Frunexian is a parenteral Factor XIa inhibitor designed for acute hospital settings.

Cadrenal Therapeutics is headquartered in Ponte Vedra, Florida, United States.

Cadrenal Therapeutics maintains a reputation as a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs in cardiovascular and renal diseases. Its focus on advancing novel anticoagulant programs aims to improve safety and therapeutic predictability for patients underserved by existing treatments. The company's collaboration with Abbott Global Enterprises Limited to evaluate Tecarfarin also contributes to its professional standing.

Cadrenal Therapeutics' stock ownership is a mix of institutional, insider, and retail investors. Approximately 5.85% of the company's stock is held by institutional shareholders. Insiders own about 53.11% of the company, with John Raymond Murphy being the largest individual shareholder. Retail investors hold approximately 41.03% of the stock.